Acadia submits MAA to EMA for Rett syndrome therapy
Acadia Pharmaceuticals has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for trofinetide, aimed at treating…
Central Nervous System
-
-
Eisai and Biogen’s subcutaneous Leqembi set for FDA review
Eisai and Biogen are one step away from deploying a more convenient version of their jointly developed Alzheimer’s treatment Leqembi…
-
Neumora shares sink following Phase III flop in MDD
Neumora Therapeutics saw a drop of more than 80% in its share price following the announcement of a Phase III…
-
Astellas and Sangamo sign capsid deal for neurological diseases
Astellas Pharma and Sangamo Therapeutics have signed a licence agreement for a neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, aimed at…
-
Reprieve for WuXi as Biosecure vote likely pushed to 2025
The Biosecure Act was left out of a key US defence bill that passed in the House last week, in…
-
Muna-GSK alliance to fast-track Alzheimer’s disease treatments
Muna Therapeutics has entered a research alliance with GSK to expedite Alzheimer's disease treatments by discovering and validating new drug…
-
Lundbeck acquires all outstanding shares of Longboard Pharma
Lundbeck has completed the acquisition of all outstanding shares of Longboard Pharmaceuticals, to bolster its capabilities in the neuro-rare disease…
-
Novartis and PTC Therapeutics link to develop Huntington’s therapy
Novartis has entered a worldwide licensing and partnership agreement with PTC Therapeutics to develop PTC518, a potential oral therapy for…
-
CBC acquires UCB’s neurology and allergy business in China
CBC Group, in partnership with the Mubadala Investment Company, has completed the strategic acquisition of Union Chimique Belge's (UCB) mature…
-
Acadia signs agreement with Saniona to commercialise SAN711
Acadia Pharmaceuticals has secured an exclusive global licence from Saniona to develop and commercialise SAN711 for essential tremor, a neurological…
